Publisher's Synopsis
Drugs in Context is an independent, peer reviewed and practice orientated review of all the significant data on a specific drug, placed in the context of the disease and clinical practice setting. Ezetimibe Editorial: "Whilst the evidence-base for lipid-lowering in CVD prevention is huge, much needs to be done to translate this into routine clinical practice." Disease Overview: "Raised cholesterol, in particular low density lipoprotein cholesterol (LDL-C), appears to be a pivotal risk factor in the development of coronary heart disease (CHD)." Drug Review: "Ezetimibe, 10 mg once daily, favourably modifies the lipid profile and therefore offers a useful alternative to patients who cannot tolerate statins or for those with mild hypercholesterolaemia who require modest LDL-C reductions." Improving Practice: "The burden of cardiovascular disease in the UK is large and is likely to increase as the population ages. At current rates, nearly half the population will die from a cardiovascular cause and so the problem impacts on all healthcare professionals."
